North America Alzheimer’s Disease Therapeutics And Diagnostics Market Forecast 2020-2028

North America Alzheimer’s Disease Therapeutics And Diagnostics Market Forecast 2020-2028

KEY FINDINGS
The North American Alzheimer’s disease therapeutics and diagnostics market is growing and evaluated to reach a CAGR of 5.07% over the projected period of 2020-2028. As the prevalence of Alzheimers disease increases, the need for new therapies also rises for the diagnosis and treatment of the disease. The pharmaceutical industry is focusing on developing disease-modifying drugs that are influencing the market growth in the region.

MARKET INSIGHTS
The market growth of Alzheimer’s disease therapeutics and diagnostics in North America is studied further by dividing the region into countries such as the US and Canada. According to the Canadian Institutes of Health Research, a large number of senior citizens diagnosed with some form of dementia, and the statistics are expected to rise by 66% by 2031. Alzheimers disease is the most common cause of dementia, contributing approximately 64% of all dementia cases. If the growth continues at the current rate, the cost caregivers and the healthcare system will bear a huge cost by 2031. Currently, the available drugs do not cure the disease, and their benefits decrease with time. Hence, public and private health insurers have coverage limitations of drugs to people who meet certain conditions. Coverage might stop even if a person’s symptoms have not changed. Therefore, the Provincial government, which spends an average of 38% of its budget on healthcare, is responsible for healthcare facilities in Canada. Pharmaceutical companies sponsor most of the AD drug trials, and urge the provinces to pay for the drugs as public insurance coverage generates more sales. It is expected that the high prevalence of AD, growing awareness, and increasing demand for better drug coverage will surge the Canadian market.

COMPETITIVE INSIGHTS
Baxter International Inc., Amarantus Bioscience Holdings Inc., GE Healthcare, Biogen Inc., Merck & Co. Inc., Allergan PLC (Allergan) , etc. are some of the prominent companies operating in the market.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments.


1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations
2. Executive Summaries
2.1. Market Size & Estimates
2.2. Market Overview
3. Market Dynamics
3.1. Parent Market Analysis: Alzheimer’s Disease Therapeutics And Diagnostics Market
3.2. Market Definition
3.3. Key Drivers
3.3.1. Growing Geriatric Population
3.3.2. Rise In The Pervasiveness Of Alzheimer’s Disease
3.3.3. Emerging Novel Diagnostic Technologies
3.3.4. Increasing Pipeline Drugs
3.4. Key Restraints
3.4.1. Failure Of The Late-stage Drugs
3.4.2. Stringent Government Regulations
3.4.3. High Cost Of Therapies Used For The Treatment Of Alzheimer’s Disease
4. Key Analytics
4.1. Porter’s Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’s Power
4.1.4. Supplier’s Power
4.1.5. Competitive Rivalry
4.2. Key Buying Criteria
4.2.1. Price
4.2.2. Efficiency
4.2.3. Safety
4.3. Etymology Of Alzheimer’s Disease Therapeutics And Diagnostics Market
4.4. Supply Chain Analysis
4.4.1. Research And Development
4.4.2. Raw Materials
4.4.3. Manufacturing
4.4.4. Wholesalers
4.4.5. End User
4.5. Phases And Sternness Of Alzheimer’s Disease
4.6. Opportunity Matrix
4.7. Vendor Landscape
4.8. Key Investment Insights
5. Market By Therapeutics And Diagnostics
5.1. Therapeutics
5.1.1. Therapeutics By Drugs
5.1.1.1. Marketed Drugs
5.1.1.2. Pipeline Drugs
5.1.2. Therapeutics By Disease Stage
5.1.2.1. Late Stage: Severe Ad
5.1.2.2. Early/Middle Stage: Mild To Moderate Ad
5.1.2.3. Prodromal Stage
5.1.3. Therapeutics By Generic And Branded
5.1.3.1. Branded
5.1.3.2. Generic
5.2. Diagnostics
5.2.1. Lumbar Puncture Test
5.2.2. Positron Emission Tomography
5.2.3. Electroencephalography
5.2.4. Magnetic Resonance Imaging
5.2.5. Computed Tomography
5.2.6. Other Diagnostics
6. Geographical Analysis
6.1. North America
6.1.1. The United States
6.1.2. Canada
7. Company Profiles
7.1. Allergan Plc
7.2. Amarantus Bioscience Holdings Inc.
7.3. Baxter International Inc.
7.4. Biogen Inc.
7.5. Cognoptix, Inc.
7.6. Eisai Co. Ltd
7.7. Eli Lilly & Company
7.8. F. Hoffmann-la Roche
7.9. Ge Healthcare
7.10. Johnson & Johnson
7.11. Lupin Limited
7.12. Merck & Co. Inc.
7.13. Novartis Ag
7.14. Pfizer Inc.
7.15. Sun Pharmaceuticals Industries Ltd.
List Of Tables
Table 1: Market Snapshot - Alzheimer’s Disease And Therapeutics
Table 2: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Therapeutics And Diagnostics, Historical Years, 2016-2019 (In $ Million)
Table 3: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Therapeutics And Diagnostics, Forecast Years, 2020-2028 (In $ Million)
Table 4: North America Therapeutics Market, Historical Years, 2016-2019 (In $ Million)
Table 5: North America Therapeutics Market, Forecast Years, 2020-2028 (In $ Million)
Table 6: North America Therapeutics Market, By Drugs, Historical Years, 2016-2019 (In $ Million)
Table 7: North America Therapeutics Market, By Drugs, Forecast Years, 2020-2028 (In $ Million)
Table 8: North America Marketed Drugs Market, Historical Years, 2016-2019 (In $ Million)
Table 9: North America Marketed Drugs Market, Forecast Years, 2020-2028 (In $ Million)
Table 10: North America Pipeline Drugs Market, Historical Years, 2016-2019 (In $ Million)
Table 11: North America Pipeline Drugs Market, Forecast Years, 2020-2028 (In $ Million)
Table 12: North America Therapeutics Market, By Drugs, Historical Years, 2016-2019 (In $ Million)
Table 13: North America Therapeutics Market, By Drugs, Forecast Years, 2020-2028 (In $ Million)
Table 14: North America Late Stage: Severe Ad Market, Historical Years, 2016-2019 (In $ Million)
Table 15: North America Late Stage: Severe Ad Market, Forecast Years, 2020-2028 (In $ Million)
Table 16: North America Early/Middle Stage: Mild To Moderate Ad Market, Historical Years, 2016-2019 (In $ Million)
Table 17: North America Early/Middle Stage: Mild To Moderate Ad Market, Forecast Years, 2020-2028 (In $ Million)
Table 18: North America Prodromal Stage Market, Historical Years, 2016-2019 (In $ Million)
Table 19: North America Prodromal Stage Market, Forecast Years, 2020-2028 (In $ Million)
Table 20: North America Therapeutics Market, By Drugs, Historical Years, 2016-2019 (In $ Million)
Table 21: North America Therapeutics Market, By Drugs, Forecast Years, 2020-2028 (In $ Million)
Table 22: North America Branded Market, Historical Years, 2016-2019 (In $ Million)
Table 23: North America Branded Market, Forecast Years, 2020-2028 (In $ Million)
Table 24: North America Generic Market, Historical Years, 2016-2019 (In $ Million)
Table 25: North America Generic Market, Forecast Years, 2020-2028 (In $ Million)
Table 26: North America Diagnostics Market, Historical Years, 2016-2019 (In $ Million)
Table 27: North America Diagnostics Market, Forecast Years, 2020-2028 (In $ Million)
Table 28: North America Diagnostics Market, By Type, Historical Years, 2016-2019 (In $ Million)
Table 29: North America Diagnostics Market, By Type, Forecast Years, 2020-2028 (In $ Million)
Table 30: North America Lumbar Puncture Test Market, Historical Years, 2016-2019 (In $ Million)
Table 31: North America Lumbar Puncture Test Market, Forecast Years, 2020-2028 (In $ Million)
Table 32: North America Positron Emission Tomography Market, Historical Years, 2016-2019 (In $ Million)
Table 33: North America Positron Emission Tomography Market, Forecast Years, 2020-2028 (In $ Million)
Table 34: North America Electroencephalography Market, Historical Years, 2016-2019 (In $ Million)
Table 35: North America Electroencephalography Market, Forecast Years, 2020-2028 (In $ Million)
Table 36: North America Magnetic Resonance Imaging Market, Historical Years, 2016-2019 (In $ Million)
Table 37: North America Magnetic Resonance Imaging Market, Forecast Years, 2020-2028 (In $ Million)
Table 38: North America Computed Tomography Market, Historical Years, 2016-2019 (In $ Million)
Table 39: North America Computed Tomography Market, Forecast Years, 2020-2028 (In $ Million)
Table 40: North America Other Diagnostics Market, Historical Years, 2016-2019 (In $ Million)
Table 41: North America Other Diagnostics Market, Forecast Years, 2020-2028 (In $ Million)
Table 42: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Country, Historical Years, 2016-2019 (In $ Million)
Table 43: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Country, Forecast Years, 2020-2028 (In $ Million)
List Of Figures
Figure 1: Pipeline Drugs Related To Alzheimer’s Disease
Figure 2: Costs Of Care For People With Alzheimer’s And Other Dementias, 2017 ($ Billion)
Figure 3: Porter’s Five Force Analysis
Figure 4: Supply Chain Analysis
Figure 5: Opportunity Matrix
Figure 6: Vendor Landscape
Figure 7: Key Investment Insights
Figure 8: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Therapeutics, 2020-2028 ($ Million)
Figure 9: North America Therapeutics Market, By Marketed Drugs, 2020-2028 ($ Million)
Figure 10: North America Therapeutics Market, By Pipeline Drugs, 2020-2028 ($ Million)
Figure 11: North America Therapeutics Market, By Late Stage: Severe Ad, 2020-2028 ($ Million)
Figure 12: North America Therapeutics Market, By Early/Middle Stage: Mild To Moderate Ad, 2020-2028 ($ Million)
Figure 13: North America Therapeutics Market, By Prodromal Stage, 2020-2028 ($ Million)
Figure 14: North America Therapeutics Market, By Branded, 2020-2028 ($ Million)
Figure 15: North America Therapeutics Market, By Generic, 2020-2028 ($ Million)
Figure 16: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, By Diagnostics, 2020-2028 ($ Million)
Figure 17: North America Diagnostics Market, By Lumbar Puncture Test, 2020-2028 ($ Million)
Figure 18: North America Diagnostics Market, By Positron Emission Tomography, 2020-2028 ($ Million)
Figure 19: North America Diagnostics Market, By Electroencephalography, 2020-2028 ($ Million)
Figure 20: North America Diagnostics Market, By Magnetic Resonance Imaging, 2020-2028 ($ Million)
Figure 21: North America Diagnostics Market, By Computed Tomography, 2020-2028 ($ Million)
Figure 22: North America Diagnostics Market, By Other Diagnostics, 2020-2028 ($ Million)
Figure 23: North America Alzheimer’s Disease Therapeutics And Diagnostics Market, Country Outlook, 2019 & 2028 (In %)
Figure 24: The United States Alzheimer’s Disease Therapeutics And Diagnostics Market, 2020-2028 (In $ Million)
Figure 25: Canada Alzheimer’s Disease Therapeutics And Diagnostics Market, 2020-2028 (In $ Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook